Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market
Nordicus Partners Corporation (OTCQB: NORD), a financial consulting firm focused on Nordic-US life sciences market entry, has submitted an application to uplist its common stock from the OTCQB Market to the Nasdaq Capital Market.
The company, which completed two acquisitions last year and is advancing its drug development pipeline in periodontitis and oral leukoplakia, aims to enhance shareholder value through increased visibility, liquidity, and access to institutional investors. The stock will continue trading under the symbol NORD on OTCQB pending Nasdaq approval.
Nordicus Partners Corporation (OTCQB: NORD), societ脿 di consulenza finanziaria specializzata nell鈥檌ngresso sul mercato nordico-statunitense delle scienze della vita, ha presentato domanda per trasferire le proprie azioni comuni dall鈥橭TCQB al Nasdaq Capital Market.
L鈥檃zienda, che lo scorso anno ha portato a termine due acquisizioni e sta sviluppando una pipeline per trattamenti contro la parodontite e la leucoplachia orale, punta a creare valore per gli azionisti aumentando visibilit脿, liquidit脿 e accesso a investitori istituzionali. Le azioni continueranno a essere negoziate con il simbolo NORD su OTCQB in attesa dell鈥檃pprovazione da parte del Nasdaq.
Nordicus Partners Corporation (OTCQB: NORD), una consultora financiera centrada en la entrada al mercado n贸rdico-estadounidense de ciencias de la vida, ha presentado una solicitud para listar sus acciones ordinarias desde el OTCQB en el Nasdaq Capital Market.
La compa帽铆a, que complet贸 dos adquisiciones el a帽o pasado y est谩 avanzando en su cartera de f谩rmacos para periodontitis y leucoplasia oral, busca aumentar el valor para los accionistas mediante mayor visibilidad, liquidez y acceso a inversores institucionales. Las acciones seguir谩n cotizando con el s铆mbolo NORD en OTCQB mientras se espera la aprobaci贸n de Nasdaq.
Nordicus Partners Corporation (OTCQB: NORD)電� 攵侅湢霟解�戨甑� 氚旍澊鞓ぢ缝儩氇呹臣頃� 鞁滌灔 歆勳稖鞚� 歆�鞗愴晿電� 旮堨湹 旎劋韺� 須岇偓搿滌劀 氤错喌欤茧ゼ OTCQB 鞁滌灔鞐愳劀 雮橃姢雼� 旌愴敿韯� 毵堨紦鞙茧 鞚挫爠頃橁赴 鞙勴暅 靸侅灔 鞁犾箔靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.
須岇偓電� 歆�雮滍暣 霊� 瓯挫潣 鞚胳垬毳� 鞕勲頄堨溂氅� 旃橃＜鞐缄臣 甑皶氚彪皹歃� 旃橂鞝� 臧滊皽 韺岇澊頂勲澕鞚胳潉 歆勴枆 欷戩瀰雼堧嫟. 氤措嫟 雴掛潃 臧�鞁滌劚, 鞙犽彊靹� 氚� 旮瓣磤韴瀽鞛� 鞝戧芳靹膘潉 韱淀暣 欤检＜ 臧�旃橂ゼ 鞝滉碃頃橂姅 瓴冹澊 氇╉憸鞛呺媹雼�. 欤检嫕鞚� 雮橃姢雼� 鞀轨澑 雽�旮� 欷戩棎霃� 旮绊樃 NORD搿� OTCQB鞐愳劀 瓿勳啀 瓯半灅霅╇媹雼�.
Nordicus Partners Corporation (OTCQB: NORD), cabinet de conseil financier sp茅cialis茅 dans l鈥檈ntr茅e sur le march茅 nordique鈥慳m茅ricain des sciences de la vie, a d茅pos茅 une demande pour transf茅rer ses actions ordinaires de l鈥橭TCQB vers le Nasdaq Capital Market.
La soci茅t茅, qui a finalis茅 deux acquisitions l鈥檃n dernier et fait progresser sa pipeline de m茅dicaments pour la parodontite et la leucoplasie buccale, vise 脿 accro卯tre la valeur pour les actionnaires gr芒ce 脿 une meilleure visibilit茅, une liquidit茅 renforc茅e et un acc猫s aux investisseurs institutionnels. L鈥檃ction continuera d鈥櫭猼re n茅goci茅e sous le symbole NORD sur l鈥橭TCQB en attendant l鈥檃pprobation du Nasdaq.
Nordicus Partners Corporation (OTCQB: NORD), eine Finanzberatungsfirma mit Fokus auf den nordisch鈥慤S鈥慳merikanischen Life鈥慡ciences鈥慚arkteintritt, hat einen Antrag gestellt, ihre Stammaktien vom OTCQB鈥慚arkt an das Nasdaq Capital Market zu verlegen.
Das Unternehmen, das im vergangenen Jahr zwei 脺bernahmen abgeschlossen hat und seine Wirkstoffpipeline gegen Parodontitis und orale Leukoplakie vorantreibt, will den Aktion盲rswert durch h枚here Sichtbarkeit, Liquidit盲t und Zugang zu institutionellen Investoren steigern. Die Aktie wird bis zur Nasdaq鈥慫ulassung weiterhin unter dem K眉rzel NORD am OTCQB gehandelt.
- Potential uplisting to Nasdaq could increase stock visibility and liquidity
- Company has completed two strategic acquisitions
- Advancing proprietary drug development pipeline in periodontitis and oral leukoplakia
- Potential for improved access to institutional investors and capital
- Nasdaq listing approval is not guaranteed
- Current trading on less prominent OTCQB market
BEVERLY HILLS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (鈥淣ordicus鈥� or the 鈥淐ompany鈥�), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces it has applied to uplist its common stock (the 鈥淐ommon Stock鈥�) to the Nasdaq Capital Market (鈥淣asdaq鈥�). The Common Stock will continue to trade on the OTCQB Market until the uplisting is approved.
鈥淲e are pleased to announce our application to uplist our shares on Nasdaq,鈥� said Henrik Rouf, Nordicus鈥� Chief Executive Officer. 鈥淔ollowing the completion of two acquisitions last year, and with the advancement of our proprietary drug development pipeline in periodontitis and oral leukoplakia, we believe the time is right to move to a globally recognized exchange. A Nasdaq listing will not only provide greater visibility and liquidity for our shareholders, but also strengthen our ability to attract institutional investors and access capital on more favorable terms to accelerate the growth of our business.鈥�
The listing of Nordicus鈥� Common Stock on Nasdaq is subject to the approval of Nasdaq and the satisfaction of all applicable listing criteria and requirements. We are confident that Nordicus will meet all applicable listing criteria and requirements, but no assurance can be given that such application will be approved or that such listing will be completed. The Common Stock will continue to trade on the OTCQB under its current symbol NORD pending approval of a Nasdaq listing.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥減roject,鈥� 鈥渆stimate,鈥� 鈥渋ntend,鈥� 鈥渃ontinue,鈥� 鈥渃onfident鈥� or 鈥渂elieve鈥� or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.聽
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
Tel +1 310 666 0750
FAQ
What is Nordicus Partners Corporation's (NORD) plan to uplist to Nasdaq?
What are the benefits of Nordicus (NORD) uplisting to Nasdaq?
What business areas does Nordicus Partners (NORD) operate in?
How many acquisitions has Nordicus (NORD) completed recently?
What happens to NORD stock while waiting for Nasdaq approval?
